Results 61 to 70 of about 12,091 (231)
Clinical Pharmacology &Therapeutics, EarlyView.Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović +11 more
wiley +1 more source
Biology of Myeloproliferative Malignancies
Клиническая онкогематология, 2016 Chronic myeloproliferative diseases (WHO, 2001), or myeloproliferative neoplasms/malignancies (MPN) (WHO, 2008), are clonal diseases characterized by proliferation of one or more myelopoietic cell line in the bone marrow with signs of unimpaired terminal
A. L. Melikyan +1 more
doaj +1 more source
PROTEOMICS, EarlyView.ABSTRACT Triple‐negative breast cancer (TNBC) represents the most aggressive subtype with limited therapeutic options and the poorest clinical outcomes. Using high‐resolution nUPLC‐QTOF‐MS/MS, we performed comprehensive proteomic profiling of TNBC cell lines representing disease progression stages: HCC‐1937 (stage IIB), HCC‐1599 (stage IIIA), and MDA ...
Claudia Sissely Chaviano‐Montes de Oca +7 more
wiley +1 more source
Journal of Hematology & Oncology, 2016 Background Somatic calreticulin (CALR), Janus kinase 2 (JAK2), and thrombopoietin receptor (MPL) mutations essentially show mutual exclusion in myeloproliferative neoplasms (MPN), suggesting that they activate common oncogenic pathways.
Lijuan Han +7 more
doaj +1 more source
Smart Molecules, EarlyView.The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou +4 more
wiley +1 more source
Journal of Experimental & Clinical Cancer Research, 2012 Background The management of patients with glioblastoma multiforme is difficult. Poor results have led to a search for novel therapeutic approaches. Gene therapy that could be both anti-invasive and antiangiogenic would be ideal.
Liu Xin-Li +6 more
doaj +1 more source
Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia [PDF]
, 2016 The development of acute lymphoblastic leukemia in an existing myeloproliferative neoplasm is rare with historical cases unable to differentiate between concomitant malignancies or leukemic transformation.
Karl Haslam +8 more
core +1 more source
Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma
Allergy, EarlyView.This study investigates the effect of mepolizumab on the proteomic and transcriptomic profile of blood eosinophils in SEA patients. Mepolizumab reduces the migratory capacity and effector‐related molecular signatures of circulating eosinophils in SEA patients.
Pablo Miguéns‐Suárez +14 more
wiley +1 more source
Mediterranean Journal of Hematology and Infectious Diseases, 2020 Somatic mutations of exon 9 of calreticulin gene (CALR) were diagnosis and prognosis importance found in patients with JAK2V617F-negative essential thrombocythemia (ET).
Yi-Chang Liu +14 more
doaj +1 more source
British Journal of Haematology, EarlyView.Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source